VIR-1388
- Generic Name
- VIR-1388
To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV
Phase 1
Active, not recruiting
- Conditions
- HIV I Infection
- Interventions
- Biological: Placebo
- First Posted Date
- 2023-05-11
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Vir Biotechnology, Inc.
- Target Recruit Count
- 95
- Registration Number
- NCT05854381
- Locations
- 🇿🇦
Setshaba Research Centre CRS, Soshanguve, Gauteng, South Africa
🇺🇸Alabama CRS, Birmingham, Alabama, United States
🇺🇸The Hope Clinic of the Emory Vaccine Center CRS, Decatur, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath